Talk:Combretastatin

Assessment comment - 2007
Substituted at 12:05, 29 April 2016 (UTC)

Untitled
Hello I started this page. Combretastatin A-4 is the correct name and the structure is also correct. Combrestatin is incorrect or at the very least a variance of the correct nomenclature. Combretastatin A-4 is part of a larger family of natural products and synthetic analogs. When I search for that CAS number (117048-59-6) I also see Combretastatin A-4 results. Definitely a confusing mistake! Also, the ChemIDplus result for NAME: Combretastatin A-4 RN: 117048-59-6 shows the trans isomer which is technically correct, although the pharmacologically active CA-4 is the cis isomer. Silverweed 07:42, 13 November 2007 (UTC)

Edited the page to reflect a few recent updates, namely that CA-4 has reached its first phase III clinical trial (yay!) and is in numerous phase I and II trials. Check www.clinicaltrials.gov (search for combretastatin) for more info. Silverweed 07:53, 13 November 2007 (UTC)

Is Combretastatin supposed to be on the Statin page? If not (if it's not a statin), maybe that fact should be clarified in this article? Also, if Combretastatin is a statin (which I honestly don't know), then the Statin page should be updated with some information on the anti-cancer effects of Combretastatin. europrobe (talk) 17:29, 28 January 2008 (UTC)

Combretastatin is not a Statin, I'm not sure what the origin of the name is. Silverweed (talk) 11:02, 5 April 2008 (UTC)

List of references
The following list of references was added to the article, but apparently are not used to support specific content in the article. I'm moving them here in case anyone would like to use them to expand this article. -- Ed (Edgar181) 19:16, 16 August 2011 (UTC)
 * Sackett, D; Varma, J. Molecular mechanism of Colchicine action: induced local unfolding of beta tubulin Biochemistry, 1993, 32, 13560-13565.
 * Hadfield, J; Ducki, S; Hirst, N; McGown, A. Tubulin and microtubules as targets for anticancer drugs Progress in Cell Cycle Research, 2003, 5, 309-325.
 * Hinnen, P. "Vascular disrupting agents in clinical development" British Journal of Cancer (2007) 96, 1159-1165.
 * Jordan, Mary Ann "Microtubules as a target for anticancer drugs" Nature Reviews Cancer, 2004, 4, 253-265
 * Monaco, R. R; Gardiner, W. C; Kirschner, S. Semiemperical Studies of Ring Twisting in cis-Stilbene and Related Biomolecules International Journal of Quantum Chemistry, 1999, 71, 57-62.
 * Maya, Ana B. S; Perez-Melero, Concepcion; Mateo, Carmen; Alonso, Dulce; Fernandez, Jose Luis; et al. Further Napthylcombretastatins. An Investigation on the Role of the Naphthalene Moiety J. Med. Chem, 2005, 48, 556-568.
 * Monk, Keith A; Siles, Rogelio; Hadimani, Mallinath B; Mugabe, Benon E; et al. Design, Synthesis, and Biological Evaluation of Combretastatin Nitrogen-Containing Derivatives as Inhibitors of Tubulin Assembly and Vascular Disrupting Agents Bioorg. Med. Chem, 2006, 14, 3231-3244.
 * Tozer, G. "Disrupting tumour blood vessels" Nature Reviews Cancer, 2005, 5, 432-435
 * Pati, H; Taherbhai, Z; Forrest, L; Wicks, M; Bailey, S; Staples, A; et al. A Stereospecific Route for the Preparation of Trans-Combretastatin Analogs: Synthesis and Cytotoxicity Letters in Drug Design & Discovery, 2004, 1, 275-278.
 * Patterson, D. “Vascular Damaging Agents” Clinical Oncology, 2007, 19, 443-456
 * Babu B, Lee M, Lee L, Strobel R, Brockway O, Nickols A, Sjoholm R, Tzou S, Chavda S, Desta D, Fraley G, Siegfried A, Pennington W, Hartley RM, Westbrook C, Mooberry SL, Kiakos K, Hartley JA, Lee M."Acetyl analogs of combretastatin A-4: Synthesis and biological studies".Bioorg Med Chem. 2011 Apr 1;19(7):2359-67. Epub 2011 Feb 17
 * Megan Lee, Olivia Brockway, Armaan Dandavati, Samuel Tzou, Robert Sjoholm, Alexis Nickols, Balaji Babu, Sameer Chavda, Susan L. Mooberry, Gregory Fraley, Moses Lee."Design and synthesis of novel enhanced water soluble hydroxyethyl analogs of combretastatin A-4".Bioorg Med Chem Lett. 2011 Apr 1;21(7):2087-91. Epub 2011 Feb 3.